Sex differences in P50 inhibition defects with psychopathology and cognition in patients with first-episode schizophrenia.

Progress in Neuro-psychopharmacology & Biological Psychiatry
Luyao XiaXiang Yang Zhang

Abstract

A large number of studies have shown that the pathophysiology of schizophrenia may be involved in sensory gating that appears to be P50 inhibition. However, few studies have investigated the relationship between clinical symptoms, cognitive impairment and sensory gating disorders in patients with first-episode schizophrenia. The purpose of this study was to explore the sex differences in the relationship between clinical symptoms, cognitive impairment and P50 inhibition defects in patients with first-episode schizophrenia, which has not been reported. 130 patients with first-episode schizophrenia (53 males and 77 females) and 189 healthy controls (87 males and 102 females) participated in the study. Positive and Negative Syndrome Scale (PANSS) was used to evaluate the patients' psychopathological symptoms, and the 64-channel electroencephalogram (EEG) system was used to record the P50 inhibition. Male patients had higher PANSS negative symptom, general psychopathology, cognitive factor and total scores than female patients (all p < 0.01). The S1 amplitude was smaller in male than female patients (all p < 0.05). Multiple regression analysis showed that in male patients, S1 latency was contributor to negative symptoms, while S1 l...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Sep 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C R BreeseS Leonard
Mar 23, 2001·Acta Psychiatrica Scandinavica. Supplementum·A Riecher-Rössler, H Häfner
Jul 18, 2001·Comprehensive Psychiatry·J UsallUNKNOWN Assessment Research Group in Schizophrenia (NEDES)
Jun 28, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sophie Grigoriadis, Mary V Seeman
Oct 3, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Robin G McCreadie, UNKNOWN Scottish Comorbidity Study Group
Mar 26, 2003·Psychoneuroendocrinology·H Häfner
May 29, 2003·Current Drug Targets. CNS and Neurological Disorders·J K SimoskyR Freedman
Jan 15, 2004·The Journal of Pharmacology and Experimental Therapeutics·Massimo PierucciEnnio Esposito
Dec 8, 2004·Journal of Psychopharmacology·Kristi A SaccoTony P George
Jul 15, 2005·Psychiatry Research·Sandrine Louchart-de la ChapelleFlorence Thibaut
Feb 14, 2006·Schizophrenia Bulletin·David PotterRobert W Buchanan
May 3, 2006·Addictive Behaviors·John M StarrLawrence J Whalley
Jun 7, 2006·Archives of General Psychiatry·Ann OlincyRobert Freedman
Jul 18, 2006·Biological Psychiatry·Sherry Leonard, Robert Freedman
Nov 30, 2006·European Journal of Endocrinology·Olivier Beauchet
Mar 14, 2007·International Review of Neurobiology·Laura F Martin, Robert Freedman
Mar 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leah H RubinPauline M Maki
May 2, 2007·Proceedings of the National Academy of Sciences of the United States of America·Morgane BessonPhilippe Faure
Sep 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Adriano FloraHuda Y Zoghbi
Jan 12, 2008·Psychiatry Research·Julie V PattersonWilliam E Bunney
Apr 3, 2008·The American Journal of Psychiatry·Robert FreedmanWilliam R Kem
Jun 11, 2008·Archives of Internal Medicine·Séverine SabiaArchana Singh-Manoux
Oct 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·R SattaA Guidotti
Jul 25, 2009·Schizophrenia Research·Colleen A BrennerWilliam P Hetrick
Sep 25, 2009·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Robert A PhilibertMeg Gerrard
Feb 10, 2010·Journal of Abnormal Psychology·Cindy M YeeKenneth L Subotnik
Mar 26, 2010·Journal of Psychiatric Research·Xiang Yang ZhangThomas R Kosten
Apr 20, 2010·The Australian and New Zealand Journal of Psychiatry·Chuan-Yue WangGabor S Ungvari
Apr 24, 2010·Psychopharmacology·Stephen J HeishmanEdward G Singleton
Jun 25, 2010·Annals of General Psychiatry·Akihiro ShiinaKenji Hashimoto
Jul 17, 2010·The American Journal of Psychiatry·Ashley K SmithJosé M Cañive
Oct 16, 2010·Schizophrenia Research·Leah H RubinPauline M Maki
May 20, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A ÜçokUNKNOWN EGOFORS
Jun 21, 2011·Schizophrenia Research·Leah H RubinPauline M Maki
Oct 14, 2011·Drug and Alcohol Dependence·Timothy C DurazzoSara Jo Nixon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.